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Significance of this study 1 
What is already known about this subject?  2 
 Pi*Z and Pi*S are the most important genetic variants causing alpha1-antitrypsin deficiency (AATD). 3 
 No reliable data on hepatobiliary phenotype exist for individuals with Pi*SS and Pi*SZ genotype, despite 4 
the fact that both genotypes are seen in ~1:500 Caucasians. 5 
 The vast majority of AATD subjects remain undiagnosed during their lifetime and this fact complicates 6 
AATD phenotyping. 7 
What are the new findings?  8 
 In a large community-based Biobank as well as in a multinational cohort, subjects with Pi*SZ genotype 9 
were markedly predisposed to liver fibrosis and seemed to be predisposed to primary liver cancer.  10 
 Compared to the characteristic severe AATD genotype Pi*ZZ, Pi*SZ genotype causes intermediate 11 
hepatobiliary phenotype, while Pi*SS does not seem to have major hepatobiliary consequences. 12 
How might it impact on clinical practice in the foreseeable future?  13 
 Our study defines the hepatic risks associated with the major AATD genotypes. These data, together with 14 
the individual situation/susceptibility factors, should guide the counseling and management of AATD 15 
individuals.  16 
 The observed association with primary liver cancer should promote hepatologic surveillance of AATD 17 
individuals and spur longitudinal studies characterizing the development of liver fibrosis and malignancy.  18 
  19 
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ABSTRACT  1 
Objective: Alpha-1 antitrypsin deficiency (AATD) is a common, potentially lethal inborn disorder caused by 2 
mutations in alpha-1 antitrypsin (AAT). Homozygosity for the „Pi*Z‟ variant of AAT (Pi*ZZ genotype) causes lung 3 
and liver disease, whereas heterozygous „Pi*Z‟ carriage (Pi*MZ genotype) predisposes to gallstones and liver 4 
fibrosis. The clinical significance of the more common „Pi*S‟ variant remains largely undefined and no robust data 5 
exist on the prevalence of liver tumors in AATD.  6 
Design: Baseline phenotypes of AATD individuals and non-carriers were analyzed in 482,380 participants in the UK 7 
Biobank. 1104 participants of a multinational cohort (586 Pi*ZZ, 239 Pi*SZ, 279 non-carriers) underwent a 8 
comprehensive clinical assessment. Associations were adjusted for age, sex, BMI, diabetes, and alcohol 9 
consumption.  10 
Results: Among UK Biobank participants, Pi*ZZ individuals displayed the highest liver enzyme values, the highest 11 
occurrence of liver fibrosis/cirrhosis (adjusted odds ratio (aOR)=21.7[8.8-53.7]) and primary liver cancer 12 
(aOR=44.5[10.8-183.6]). Subjects with Pi*MZ genotype had slightly elevated liver enzymes and moderately 13 
increased odds for liver fibrosis/cirrhosis (aOR=1.7[1.2-2.2]) and cholelithiasis (aOR=1.3[1.2-1.4]). Individuals with 14 
homozygous Pi*S mutation (Pi*SS genotype) harbored minimally elevated alanine aminotransferase values, but no 15 
other hepatobiliary abnormalities. Pi*SZ participants displayed higher liver enzymes, more frequent liver 16 
fibrosis/cirrhosis (aOR=3.1[1.1-8.2]) and primary liver cancer (aOR=6.6[1.6-26.9]). The higher fibrosis burden was 17 
confirmed in a multinational cohort. Male sex, age≥50years, obesity, and the presence of diabetes were associated 18 
with significant liver fibrosis. 19 
Conclusion: Our study defines the hepatobiliary phenotype of individuals with the most relevant AATD genotypes 20 
including their predisposition to liver tumors, thereby allowing evidence-based advice and individualized 21 
hepatological surveillance. 22 
 23 
Keywords: SERPINA1, Fibroscan, Pi*S, liver fibrosis, liver cirrhosis. 24 
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INTRODUCTION   1 
 AAT deficiency (AATD) is one of the most common, potentially lethal inborn disorders, with AATD-related lung 2 
and liver disease being the major drivers of morbidity and mortality.[1] Mutations in the SERPINA1 gene coding for 3 
alpha-1 antitrypsin (AAT) lead to a „gain of function‟ proteotoxic liver injury, whereas the lack of AAT in the 4 
bloodstream facilitates the development of chronic obstructive pulmonary disease (COPD) and emphysema.[1] 5 
The most common severe SERPINA1 variant is termed „Pi*Z‟ (rs28929474).[2, 3] The „Pi*S‟ variant (rs17580) is 6 
even more prevalent, but less detrimental.[1] The homozygous occurrence of „Pi*Z‟ is found in 1:2000 7 
Caucasians[2] and is termed „Pi*ZZ‟, whilst heterozygous „Pi*Z‟ carriage (termed „Pi*MZ‟ genotype) is seen in 1:30 8 
individuals of Northern European descent. The strong predisposition of „Pi*ZZ‟ individuals for lung disease is 9 
supported by a large body of evidence and reflected in clinical management guidelines.[1] The susceptibility for liver 10 
disease is less well documented.[3, 4] „Pi*ZZ‟-related liver disease displays a biphasic pattern with the first peak in 11 
early childhood as neonatal cholestasis and the second peak after 50 years of age.[1, 5] Two cross-sectional studies 12 
indicate that advanced liver fibrosis is ten to 20 times more common in „Pi*ZZ‟ subjects compared to individuals 13 
without a „Pi*Z‟ mutation (non-carriers) and revealed that the non-invasive liver stiffness measurement (LSM) via 14 
transient elastography (TE) constitute a useful surrogate of liver fibrosis.[4, 6] „Pi*MZ‟ individuals seem to carry 15 
moderately elevated odds for both lung and liver disease, and to be susceptible to gallstone disease.[1, 7] 16 
Humans carrying both the „Pi*Z‟ and the „Pi*S‟ variant (termed „Pi*SZ‟) are as frequent as 1:500 in certain 17 
geographic regions,[8] while the occurrence of homozygous carriage of the „Pi*S‟ variant (termed „Pi*SS‟) might be 18 
even higher.[9] Two studies demonstrated that „Pi*SZ‟ individuals display a less severe lung phenotype than Pi*ZZ 19 
subjects,[10, 11] whereas the extent of their liver disease was not systematically studied. Children with „Pi*SZ‟ 20 
genotype develop a clinically relevant liver disease markedly less often than Pi*ZZ individuals.[12, 13] Similar 21 
findings have been reported in adults,[14] but multiple case reports have described “idiopathic” liver cirrhosis in 22 
„Pi*SZ‟ subjects.[15] Finally, while the „Pi*SS‟ genotype is considered to confer minimal if any risks, little clinical 23 
data are available to support this directly.[16] 24 
Probably the greatest limitation when studying the AATD phenotype is the fact that the majority of AATD cases 25 
remain undiagnosed and the proportion is even higher in individuals with less severe genotypes.[1] A Swedish birth 26 
cohort-based study partially addressed this issue, but this study examined the individuals only up to 45 years of age, 27 
i.e. before the peak of AATD-related adult liver disease and focused on Pi*ZZ individuals.[17] To provide unbiased 28 
information about the hepatobiliary phenotype of individuals with major AATD genotypes, we used the UK 29 
Biobank, a community sample from the United Kingdom totaling nearly 500,000 individuals with available „Pi*Z‟ 30 
and „Pi*S‟ genotyping. To corroborate our findings, we prospectively recruited the largest, multi-national cohort of 31 
Pi*SZ subjects without previously known chronic liver disease and compared their lung- and liver-related parameters 32 
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to those of Pi*ZZ participants, and non-carriers. The goal of our study was to provide data for evidence-based 1 




Population-based UK Biobank participants (Cohort 1) 2 
The „UK Biobank‟ (UKB) is a population-based cohort study conducted in the United Kingdom, which recruited 3 
502,511 volunteers aged 37 to 73 years at baseline. All participants underwent an initial examination, which was the 4 
basis for our study and gave informed consent for genotyping and data linkage to medical reports. Ongoing inpatient 5 
hospital records beginning in 1996 were used to identify diagnoses according to ICD10 codes (international 6 
classification of diseases, 10th revision). Genotyping for both the Pi*Z (rs28929474) and Pi*S (rs17580) mutation of 7 
SERPINA1 was available in 487,503 subjects. Follow-up measurement of liver enzymes was conducted in 16,010 8 
participants. 9 
We excluded participants with viral hepatitis (ICD10: B16-B19: 713 MM, 20 MZ, 2 SZ) or risky alcohol 10 
consumption (>60g alcohol/d for men, >40g alcohol/d for women: 3775 MM, 153 MZ, 9 SZ, 3 ZZ, 4 SS). We 11 
compared SERPINA1 variants to well-known genes, that modulate the risk of liver disease, i.e. PNPLA3 p.I148M 12 
(rs738409), HSD17B13:T (rs72613567), and TM6SF2 p.E167K (rs5854926); homozygous carriers were compared 13 
with non-carriers.  14 
The presence of the following primary ICD10 codes was evaluated: Fibrosis and cirrhosis (K74.0-2+K74.6), primary 15 
liver cancer (C22.0), non-alcoholic fatty liver disease (NAFLD, K76.0), non-alcoholic steatohepatitis (NASH, 16 
K75.81), cholelithiasis (K80), emphysema (J43.1+J43.2+J43.8+J43.9), and chronic bronchitis (J44). The study has 17 
been approved by the UKB Access Committee (Project #47527). The presence of metabolic syndrome was based on 18 
the IDF (International diabetes federation) definition, which consists of central obesity (defined as waist 19 
circumference with gender and ethnicity specific values) plus any two of the following four factors: (i) raised serum 20 
triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality; (ii) reduced serum HDL 21 
cholesterol < 40 mg/dL (1.03 mmol/L) in males or < 50 mg/dL (1.29 mmol/L) in females or specific treatment for 22 
this lipid abnormality; (iii) raised systolic blood pressure (BP) ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 23 
previously diagnosed hypertension; (iv) raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or 24 
previously diagnosed type 2 diabetes. 25 
 26 
Real life cohort without previously known liver disease (Cohort 2) 27 
Study population 28 
1104 individuals were recruited as part of our global Alpha-1 Liver initiative, a multicenter registry effort for 29 
AATD-related liver disease carrying out baseline assessment, that are shown herein, as well as a prospective follow-30 
up. The majority of non-carriers and Pi*ZZ participants was previously published.[6, 7] The inclusion criteria were 31 
(i) age 18 years, (ii) the ability to provide written informed consent, and (iii) no known pregnancy. To prevent an 32 
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enrichment with individuals with liver involvement, the following exclusion criteria were used: (i) the presence of 1 
known liver disease or a liver co-morbidity identified in clinical and laboratory work-up, (ii) at least two independent 2 
visits with elevated liver enzymes in medical records prior to baseline. 3 
All participants underwent clinical and laboratory work-up including standardized questionnaires with demographic 4 
parameters, previously known chronic diseases and relevant comorbidities, as well as the evaluation of alcohol and 5 
cigarette consumption. The need for augmentation therapy and long-term oxygen therapy and the COPD assessment 6 
test (CAT) values constituted determinants of lung phenotype. AAT serum level was measured and genotyping was 7 
conducted by the responsible national AAT reference laboratories, that performed PCR analysis and/or isoelectric 8 
focusing as described.[6]  9 
The Pi*SZ population consisted of 239 subjects from ten European countries (Germany, UK, Portugal, Spain, Italy, 10 
Austria, Belgium, Ireland, Denmark, Poland) and the US (Supplementary table 1). Among the Pi*ZZ participants, 11 
413 (70.5%) were from Germany. Non-carriers (n=279) were defined as individuals with normal serum AAT levels 12 
(i.e. >110 mg/dL), in whom the presence of the „Pi*Z‟ and „Pi*S‟ variant was excluded as described.[6] 219 (78.5%) 13 
of them were recruited in Germany, 60 (21.5%) in Austria. 14 
 15 
Statistical analysis 16 
All continuous variables were analyzed by unpaired, two-tailed t-tests or Mann-Whitney U test, and by a 17 
multivariable model to account for confounders (age, sex, BMI, diabetes mellitus, and alcohol consumption) and 18 
shown as mean (standard deviation) (normal distribution) or median [IQR] (non-normal distribution). Categorical 19 
variables were displayed as relative (%) frequencies and analyzed using the Chi-square test. ORs were presented 20 
with their corresponding 95% confidence intervals (CI). Multivariable logistic regression tested for independent 21 
associations. Correlations were assessed by Spearman correlation coefficients, where appropriate. Differences were 22 
indicated as statistically significant when P<0.05. The data were analyzed using SPSS Statistics version 26 (IBM; 23 




Lung- and liver-related parameters of AATD subjects in UK Biobank (Cohort 1) 2 
The 482 380 eligible UK Biobank participants comprised 138 Pi*ZZ (frequency 1:3496), 864 Pi*SZ (1:558), 1014 3 
Pi*SS (1:476), and 17006 Pi*MZ individuals (1:28; Figure 1A). All subgroups displayed a similar age and sex 4 
distribution as well as a comparable - mostly low or moderate - alcohol consumption. While diabetes mellitus was 5 
infrequent, it was less common in Pi*ZZ subjects compared to non-carriers (5% vs. 2%, p<0.0001; Table 1). As 6 
expected, Pi*ZZ individuals showed a significantly lower FEV1/FVC ratio compared to all other genotypes despite 7 
the lowest cigarette consumption (Table 1). The percentage of individuals with FEV1/FVC < 70% was the highest 8 
among Pi*ZZ participants but was also significantly higher in Pi*SZ individuals compared to non-carriers. 9 
Regarding liver-related blood parameters, mean ALT values were significantly higher in all analyzed AATD 10 
genotypes compared to non-carriers (Table 1, Figure 2A). Pi*MZ and Pi*SZ subjects presented with higher AST 11 
values than non-carriers, however, Pi*ZZ individuals had significantly higher AST values than any other assessed 12 
AATD subgroup (Table 1, Figure 2B). Gamma-glutamyl transferase (GGT) values were comparable in non-carriers, 13 
Pi*MZ, Pi*SS, and Pi*SZ individuals, while Pi*ZZ subjects significantly more often displayed elevated GGT levels. 14 
Alkaline phosphatase (ALP) was significantly elevated in Pi*MZ and Pi*SZ participants when compared to non-15 
carriers, however, comparable to subjects without AATD mutation in Pi*ZZ, Pi*SS individuals (Table 1, Figure 2C). 16 
The odds ratio of having elevated AST was the highest in Pi*ZZ individuals (adjusted OR=4.5[2.8-7.3], p<0.0001; 17 
Figure 3) and surpassed the odds seen in established genetic liver disease modifiers such as homozygous PNPLA3 or 18 
TM6SF2 mutation (Figure 3; Supplementary tables 2-4). Pi*ZZ participants also had a moderately increased risk for 19 
elevated ALT values (adjusted OR=2.1[1.2-3.6], p<0.0001; Figure 3) with odds comparable to the ones seen in 20 
subjects with a homozygous PNPLA3 or TM6SF2 mutation (Figure 3; Supplementary tables 2,3). Individuals with 21 
Pi*MZ, Pi*SS, and Pi*SZ genotype had all significantly increased risk of presenting with elevated ALT values 22 
(OR=1.2-1.5; Figure 3). To determine, whether AATD predisposes to elevated liver enzymes even in metabolically 23 
inconspicuous individuals, we reperformed the liver enzyme analysis after exclusion of individuals with the 24 
diagnosis NAFLD (Supplementary figure 1) and after exclusion of individuals with metabolic syndrome 25 
(Supplementary figure 2). Both analyses yielded largely identical results, thereby establishing the effect of AATD 26 
mutations even in metabolically inconspicuous individuals. In line, an additional adjustment for the PNPLA3 allele 27 
as the second strongest – and due to the high frequency of the risk allele – most relevant genetic risk factor for 28 
metabolic liver disease, did not affect the results (data not shown). 29 
Next, we assessed whether the analyzed liver enzymes remain stable or fluctuate over time. Here, we took advantage 30 
of follow-up measurements that were available in a subset of UK Biobank individuals and correlated them with 31 
baseline values. Serum levels of GGT and ALP showed a strong correlation (rho=0.7-0.85; Supplementary table 5), 32 
11 
 
whereas the correlation between baseline and follow-up transaminases/bilirubin levels were somewhat weaker 1 
(Supplementary table 5), which is in line with previous reports.[18] 2 
In the least studied genotypes Pi*SS and Pi*SZ, male sex, age ≥50 years, and smoking were associated with higher 3 
rates of decreased %FEV1/FVC (Figure 4). With regard to transaminases, the presence of BMI ≥30kg/m2 or diabetes 4 
mellitus conferred an increased chance of displaying elevated values. Age ≥50 years was associated with increased 5 
AST, but not ALT values (Figure 4).  6 
  7 
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Table 1: Comparison of lung and liver phenotype in individuals with Pi*SS and Pi*SZ genotype compared to 1 












Characteristics      
Age, mean (SD), y 56.5 (8.1) 56.9 (8.1) 56.4 (8.2) 56.6 (7.8) 56.1 (8.0) 
Women, No. (%) 229 360 (54) 9 289 (55) 545(54) 474 (55) 65 (47) 
BMI, mean (SD), 
kg/m2 
27.4 (4.8) 27.3 (4.7) 27.2 (4.6) 27.0 (4.6) 26.8 (4.7) 
Alcohol, mean 8.8 (10.1) 8.6 (9.9) 8.3 (9.8) 8.6 (9.8) 8.3 (8.3) 
13 
 
Quantitative measures are expressed as mean with standard deviation or relative frequency (%). All analyses were 1 
adjusted for age, sex, BMI, presence of diabetes mellitus, and mean alcohol consumption. 2 
Abbreviations: AATD, alpha-1 antitrypsin deficiency; ALT, alanine aminotransferase; ALP, alkaline phosphatase; 3 
AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transferase; ULN, upper limit of 4 
normal (sex-specific).  5 
1p=6.0*10-12; 2p=2.5*10-11; 3p=9.5*10-9; 4p=1.5*10-7; 5p=0.032; 6p=3.0*10-9;7p=1.2*10-8; 8p=4.9*10-8; 9p=0.000006; 6 
10p=0.018; 11p=0.017; 12p=0.021; 13p=0.022; 14p=0.009; 15p=0.044; 16p=7.9*10-30; 17p=0.001; 18p=0.00007; 19p=0.006; 7 
20p=6.5*10-9; 21p=0.0004; 22p=0.001; 23p=0.009; 24p=0.046;25p=4.1*10-14; 26p=0.004; 27p=1.3*10-9; 28p=5.1*10-9; 8 
29p=7.4*10-8; 30p=2.5*10-7; 31p=0.00004; 32p=1.5*10-9; 33p=7.4*10-8; 34p=0.00001; 35p=0.00001; 36p=0.004; 9 
37p=0.013; 38p=0.028;39p=4.4*10-44; 40p=0.000003; 41p=0.019; 42p=0.003; 43p=1.0*10-24; 44p=0.00001; 45p=0.015. 10 
SI conversion factors: To convert ALT, AST, GGT, and ALP to µkat/L, multiply values by 0.0167; to convert 11 
Bilirubin to µmol/L, multiply values by 17.104. 12 
 13 
 14 
Lung- and liver-related diagnoses of AATD subjects in UK Biobank (Cohort 1) 15 
With regard to lung-related ICD codes, the diagnosis of COPD and emphysema was >20x enriched in Pi*ZZ 16 
participants compared to non-carriers. It was not more common in Pi*SS and Pi*SZ subjects, while the much more 17 
(SD), g/d 
      
Risk factors      
BMI>30 kg/m2, 
No. (%) 
130 070 (31) 5 135 (30) 300 (30) 249 (29) 37 (27) 
Diabetes mellitus, 
No. (%) 
22 399 (5) 753 (4) 57 (6) 31 (4) 3 (2) 
      
Lung status      
FEV1/VC, mean 
(SD), % 
75.9 (7.3)1 75.9 (7.5)2 76.0 (7.4)3 75.7 (7.7)4 71.5 (12.6)1,2,3,4 
FEV1/VC<70%, 
No. (%) 
59 476 (14)5,6 2 486 (15)7 148 (15)8 147 (17)5,9 44 (32)6,7,8,9 
Cigarette 
consumption, 





      
Liver status      
ALT, mean (SD), 
% of ULN 
56.2 
(32.7)16,17,18,19 
58.8 (31.6)16 59.3 (32.4)17 59.9 (30.3)18 62.5 (25.3)19 




1 235 (7.2)20,24 90 (8.9)21 76 (8.8)22 15 (10.9)23,24 
AST, mean (SD), 
% of ULN 
63.6 (26.0)25,26,27 65.2 (23.9)25,28 64.8 (24.5)29 66.0 (23.1)26,30 
75.7 
(21.8)27,28,29,30 
  AST ULN, No. 
(%) 
18 490 (4.4)31.32 847 (5.0)31,33 53 (5.2)34 46 (5.3)35 20 (14.5)32,33,34,35 
GGT, mean (SD), 
% of ULN 
73.3 (81.3) 75.6 (76.6) 77.1 (73.4) 76.4 (62.5) 83.1 (75.2) 
  GGT ULN, No. 
(%) 
68 510 (16.2)36,37 
2 849 
(16.8)36,38 
185 (18.2) 157 (18.2) 30 (21.7)37,38 
ALP, mean (SD), 
% of ULN 
72.7 (24.7)39,40 75.3 (25.7)39,41 73.3 (24.4)41,42 76.3 (24.5)40,42 72.2 (21.4) 
  ALP ULN, No. 
(%) 
46 534 (11.0)43,44 2 305 (13.6)43 121 (11.9)45 134 (15.5)44,45 16 (11.6) 
Bilirubin, mean 
(SD), mg/dl 
0.53 (0.26) 0.54 (0.26) 0.54 (0.27) 0.54 (0.28) 0.56 (0.26) 
  Bilirubin ULN, 
No. (%) 
11 692 (2.8) 528 (3.1) 31 (3.1) 28 (3.2) 7 (5.1) 
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frequent Pi*MZ individuals displayed a moderately increased odds ratio for emphysema (adjusted OR=1.6[1.3-1.9], 1 
p<0.0001; Supplementary table 6; Figure 5). Consistently with a previous publication,[19] gallstone disease was 2 
enriched in Pi*MZ carriers vs. non-carriers (adjusted OR=1.3[1.2-1.4], p<0.0001), but in none of the other AATD 3 
genotypes. The diagnosis liver fibrosis/cirrhosis was nearly 20x more common in Pi*ZZ individuals compared to 4 
non-carriers (adjusted OR=21.7[8.8-53.7], p<0.0001), but also markedly enriched in Pi*SZ subjects (adjusted 5 
OR=3.1[1.1-8.2], p=0.027) and moderately in Pi*MZ participants (1.7[1.2-2.2]; p=0.001; Supplementary table 6; 6 
Figure 5). Both Pi*SZ and Pi*ZZ individuals harbored a numerically higher risk of liver fibrosis/cirrhosis than any 7 
of the previously described genetic liver disease modifiers (Figure 6A; Supplementary tables 2-4, 6). Similarly, both 8 
Pi*SZ and Pi*ZZ subjects, but none of the other AATD genotypes, possessed a markedly increased risk for the 9 
diagnosis of primary liver cancer. Again, the risk of Pi*ZZ individuals for primary liver cancer surpassed the odds 10 
seen in individuals with other genetic modifiers, while Pi*SZ was comparable to known risk factors TM6SF2 and 11 
PNPLA3 (Figure 6, Supplementary tables 2-4, 6).  12 
A sensitivity analysis revealed that in the Pi*SZ and Pi*MZ populations, the „fibrosis/cirrhosis‟ phenotype is 13 
markedly enriched in males, obese individuals, and subjects ≥50 years old (Supplementary figure 3). 14 
 15 
Lung and liver phenotype in a multinational AATD cohort (Cohort 2) 16 
Our multinational cohort consisted of 586 Pi*ZZ subjects, 239 Pi*SZ individuals, and 279 non-carriers, all without 17 
previously known or co-existing liver disease (Table 2; Figure 1B). Pi*SZ subjects were underrepresented when 18 
compared to the community-based UK Biobank cohort. All three subgroups showed similar rates of diabetes mellitus 19 
and alcohol consumption, while differences in other demographic factors were seen (Table 2). When only 20 
participants without augmentation therapy were considered, Pi*SZ individuals showed intermediate AAT serum 21 
levels (63.8±19.8 mg/dl vs. 139.5±25.1 mg/dl in non-carriers vs. 28.3±16.0 mg/dl in Pi*ZZ, all p<0.0001, Table 2; 22 
Supplementary figure 4A). The cut-off AAT level of 99.5 mg/dL differentiated well between Pi*SZ individuals and 23 
non-carriers (sensitivity 97.9%, specificity 98.4%, Table 2; Supplementary figure 4A). Pi*SZ individuals had an 24 
intermediate lung phenotype as reflected by their CAT scores and need for long-term oxygen treatment, i.e.the 25 
levels/frequencies were higher than in non-carriers, but significantly lower/less frequent compared to Pi*ZZ 26 
individuals (Table 2). With regard to liver enzymes, Pi*SZ individuals had lower AST and ALT than Pi*ZZ subjects, 27 
while GGT was higher in Pi*SZ subjects than non-carriers. Mean ALP levels were the highest in Pi*SZ individuals 28 
(Supplementary figure 4C-F, Supplementary table 7), whereas GLDH and bilirubin levels did not show obvious 29 
differences among the subgroups (Supplementary table 7).  30 
In TE, Pi*SZ individuals had intermediate LSM values, i.e. LSMs were higher than in non-carriers (5.2±2.5 kPa vs. 31 
4.6±1.6 kPa, p=0.002), but lower than in Pi*ZZ subjects (5.2±2.5 kPa vs. 6.6±5.2 kPa; p=0.022, Table 2; 32 
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Supplementary figure 4B) and similar results were seen when only non-obese individuals were assessed 1 
(Supplementary table 8). In the entire cohort, thirteen percent of Pi*SZ individuals showed LSM values ≥7.1kPa 2 
suggesting liver fibrosis stage of at least 2 on a 0-4 scale[20] compared to 5% of non-carriers (adjusted OR=2.6 [1.1-3 
6.1], p=0.024; Table 2) and 24% of Pi*ZZ subjects (adjusted OR=0.5 [0.2-0.8], p=0.013; Table 2). Pi*SZ individuals 4 
with LSM ≥7.1 kPa had significantly higher BMI values and were more frequently diabetic (Supplementary table 9). 5 
Vice versa, diabetic individuals more frequently displayed elevated AST and ALT values than subjects without 6 
diabetes (Supplementary figure 5).  7 
The simultaneously assessed CAP as a surrogate of hepatic steatosis did not show major differences between Pi*SZ 8 
and non-carriers, nor between Pi*SZ individuals and Pi*ZZ subjects (Table 2). However, increased liver enzyme 9 
levels were seen primarily in Pi*SZ individuals with liver steatosis (as revealed by an analysis of individuals with 10 
CAP ≥248dB/m) who displayed higher AST, GGT, and ALP levels than “steatotic” non-carriers (Supplementary 11 














Table 2: Characteristics of Pi*SZ individuals in comparison to Pi*ZZ subjects and non-carriers in a multi-26 




Quantitative measures are expressed as mean with standard deviation or relative frequency (%). All multivariable 1 
analyses were adjusted for age, sex, BMI, presence of diabetes mellitus, and mean alcohol consumption. The cut-offs 2 
for non-invasive liver parameters were chosen according to etiology-unspecific recommendations: Liver stiffness 3 
7.1 kPa indicating significant liver fibrosis (fibrosis stage 2 on a 0-4 scale) and 10 kPa showing advanced 4 
fibrosis (fibrosis stage 3). Controlled-attenuation parameter (CAP) 248 dB/m suggesting the presence of steatosis 5 
grade 1, and CAP 280 dB/m indicating the presence of steatosis grade 3.  6 
+ Alcohol intake >12 g/d for women, >24 g/d for men (individuals with alcohol consumption >40 g/d females or >60 7 
g/d males had been excluded a priori).  8 
# AAT serum levels of individuals, who did not receive AAT augmentation therapy, are shown. 9 
° Liver stiffness and CAP only available in 190 Pi*SZ individuals.  10 
Abbreviations: BMI, body mass index; AAT, alpha-1 antitrypsin; CAT, chronic obstructive pulmonary disease 11 
assessment test; CAP, controlled attenuation parameter. 12 









































Characteristics        
Age, mean (SD), y 52.4 (14.6) 50.4 (16.1) 54.2 (13.2) 0.142  0.002  
Women, No. (%) 137 (49.1) 135 (56.5) 271 (46.2) 0.094  0.008  
BMI, mean (SD), kg/m2 25.6 (4.5) 26.6 (5.5) 25.0 (4.4) 0.022  <0.0001  
Alcohol, mean (SD), g/d 7.4 (9.7) 7.3 (11.9) 5.6 (9.6) 0.958  0.086  
AAT serum level#, 
mean (SD), mg/dL 
139.5 (25.1) 63.8 (19.8) 28.3 (16.0) <0.0001 <0.0001 <0.0001 <0.0001 
        
Risk factors        
BMI ≥30 kg/m², No. 
(%) 
35 (12.9) 51 (23.1) 61 (10.5) 0.003  <0.0001  
Diabetes mellitus, No. 
(%) 
13 (5.0) 7 (3.5) 20 (4.2) 0.426  0.654  
Relevant alcohol 
intake+, No. (%) 
32 (11.5) 30 (17.5) 48 (8.2) 0.070  <0.0001  
        
Lung status         
CAT score, mean (SD), 
points 
7.0 (6.0) 14.1 (9.2) 16.5 (8.1) <0.0001 <0.0001 0.022 0.004 
Cigarette consumption, 
mean (SD), py  
8.3 (16.5) 11.0 (17.1) 9.9 (13.4) 0.147 0.232 0.501 0.434 
Long-term oxygen 
treatment, No. (%) 
1 (0.4) 12 (6.5) 109 (22.6) <0.0001 0.003 <0.0001 <0.0001 
        
Liver status        
Liver stiffness°, mean 
(SD), kPa 
4.6 (1.6) 5.2 (2.5) 6.6 (5.2) 0.001 0.002 <0.0001 0.022 
Liver stiffness 7.1 
kPa°, No. (%) 
15 (5.4) 24 (12.6) 140 (23.9) 0.006 0.024 0.001 0.013 
Liver stiffness 10.0 
kPa (%)°, No. (%) 
3 (1.1) 7 (3.7) 76 (13.0) 0.057 0.199 <0.0001 0.006 
CAP°, mean (SD), 
dB/m 
249.5 (58.1) 259.6 (60.7) 264.6 (57.0) 0.122 0.056 0.401 0.132 
CAP 248 dB/m (%)°, 
No. (%) 
136 (51.9) 67 (57.3) 288 (60.8) 0.334 0.234 0.489 0.296 
CAP 280 dB/m (%)°, 
No. (%) 





We analysed the hepatobiliary phenotype of individuals with the most common AATD genotypes using the UK 3 
Biobank as a unique, openly available resource with deep genetic, physical, and health data.[21] It does not 4 
constitute an entirely representative population sample since 94% of subjects are classed as white British and 6% 5 
within ethnic minority groups, compared with 80.5% and 19.5% respectively in UK census data, and it is skewed 6 
towards higher income classes.[21] Nevertheless, it represents the best available approximation of such a cohort in 7 
that it recruited and systematically genotyped participants independently on their known SERPINA1 genotype. This 8 
approach is crucial since the vast majority of AATD individuals remain undetected and were therefore not 9 
considered in previous studies. The AAT genotyping used in our study was extracted from the UK Biobank Axiom™ 10 
array and the results remained unknown to the study subjects. The frequencies of analysed genotypes agreed well 11 
with their published occurrence in Caucasian population[8] – an observation that further validates our approach. 12 
An important limitation of our study is the difficulty to reliably identify all individuals with NAFLD and NASH 13 
since these disorders were not systematically assessed in the UK Biobank baseline visits and may remain 14 
underdiagnosed in the clinical routine. To offset this limitation, we repeated the analyses after excluding individuals 15 
with the ICD code for NAFLD as well as with presence of metabolic syndrome and demonstrated that the differences 16 
persisted in this subgroup. Moreover, liver transaminase levels significantly fluctuated over time and therefore a 17 
single measurement is not sufficient to comprehensively evaluate the liver phenotype of AATD individuals. Notably, 18 
the limited usefulness of single ALT measurements for evaluation of AATD individuals was reported previously.[22] 19 
However, our manuscript aimed to provide “typical liver enzyme levels” seen in subjects with different AATD 20 
genotypes. 21 
In the UK Biobank cohort, Pi*ZZ participants suffered a >20 times higher risk of liver fibrosis and cirrhosis as well 22 
as ~45 times higher risk of primary liver cancer. The former finding is in line with previous reports demonstrating 23 
that signs of advanced fibrosis are nine to 20-fold more common in Pi*ZZ individuals compared to people without 24 
AAT mutations as well as the observation that Pi*ZZ individuals are 20 times more likely to require liver 25 
transplantation than the general population.[6, 23] The odds of Pi*ZZ subjects to develop advanced liver 26 
fibrosis/cirrhosis are substantially higher than the ones reported for other established genetic conditions such as 27 
mutations in PNPLA3, TM6SF2, or HSD17B13 gene.[23, 24] Whilst the predisposition to liver fibrosis is now 28 
supported by a solid body of evidence, reports on liver cancer in Pi*ZZ individuals are very limited[1] and further 29 
analyses are needed. Pi*ZZ participants had the highest AST/ALT values, but their ALP levels were similar to the 30 
ones seen in non-carriers and they did not present with an increased risk of cholelithiasis. Since gallstones consist 31 
mainly of lipids such as cholesterol, the alterations in lipid metabolism that were observed in Pi*ZZ individuals (i.e. 32 
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lower serum levels of triglycerides, very low-density lipoproteins and low-density lipoproteins compared to controls) 1 
and indicate an impaired hepatic secretion of lipids might play a role.[6] Collectively, our data revealing a marked 2 
susceptibility of Pi*ZZ individuals to end-stage liver disease should prompt their thorough hepatological monitoring.   3 
The availability of genetic information allowed us to systematically study AATD genotypes, that are not assessed in 4 
clinical routine such as Pi*MZ and Pi*SS. With regard to Pi*MZ, our data confirmed previous findings of a mild 5 
increase in transaminases as well as a moderately increased risk of liver fibrosis/cirrhosis and cholelithiasis.[7, 19, 6 
24, 25] On the other hand, the increased occurrence of emphysema was seen in some, but not all population-based 7 
studies.[1] With regard to the Pi*SS genotype, our data are novel and support the current opinion that these 8 
individuals display no or only minimal predisposition to both lung and liver disease. It provides an important 9 
guidance for physicians and a relief for the carriers of this genotype.   10 
  11 
A focus of our work was on the Pi*SZ phenotype, that is underrepresented in clinical routine compared to Pi*ZZ 12 
subjects. This might be due to their less conspicuous AAT serum levels as well as their less pronounced disease 13 
phenotype.[10, 11, 26] Consistently with published data, the Pi*SZ individuals available in the UK Biobank 14 
displayed no or only minimal lung phenotype,[10, 11] while our multi-center cohort was skewed towards more lung-15 
diseased individuals, likely due to the fact that it often prompted the diagnosis of AATD. Although Pi*SZ 16 
individuals display normal or only minimally elevated transaminases, both analyzed cohorts revealed a marked 17 
predisposition to liver fibrosis. The UK Biobank cohort also suggested an increased susceptibility to primary liver 18 
cancer that was not assessed in the second cohort. The more pronounced association with liver fibrosis compared to 19 
lung emphysema might be attributable to the fact that the liver phenotype constitutes a “gain-of-function” toxicity 20 
while lung injury seems to arise due to a loss-of-function situation. Accordingly, the intermediate AAT serum levels 21 
seen in Pi*SZ individuals might be sufficient to protect the lung from proteolytic damage, while misfolding and 22 
polymerization of AAT may generate biologically relevant proteotoxic stress in the liver. The identified hetero-23 
polymerization between Pi*S and Pi*Z [27] might be responsible for the greater liver fibrosis burden than that of the 24 
Pi*MZ state despite the absence of any Pi*SS signal (suggesting no clinically significant challenge with Pi*S 25 
misfolding alone). While Pi*SZ subjects display clear predisposition to liver fibrosis and primary liver cancer, their 26 
susceptibility is markedly lower than the one seen in Pi*ZZ individuals, which is consistent with the observed lower 27 
levels of intracellular polymers and a less pronounced lung phenotype.[10, 11] 28 
In addition to the characterization of the hepatobiliary phenotype of AATD individuals, we demonstrated that male 29 
sex, obesity, diabetes, and higher age are associated with increased risk of liver fibrosis/cirrhosis as well as primary 30 
liver cancer. Notably, the same factors were previously implicated in liver fibrosis development in Pi*MZ and Pi*ZZ 31 
individuals.[4, 6, 7, 25, 28] Among them, obesity and diabetes are potentially modifiable and their effects as drivers 32 
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of non-alcoholic fatty liver disease extends beyond AATD.[29, 30] They are associated with increased oxidative 1 
stress and lipolysis and may aggravate the endoplasmic reticulum stress occurring in AATD.[31, 32] Male sex is 2 
another parameter linked to AATD since the production of AAT is stimulated by testosterone and males therefore 3 
produce higher amounts of the potentially toxic protein.[33] 4 
 In conclusion, our data characterize the hepatobiliary phenotype of adults with major AATD genotypes with a focus 5 
on Pi*SZ and should help in patient management and counselling. While Pi*ZZ individuals need a closer 6 
monitoring, the surveillance of Pi*MZ and Pi*SZ subjects needs to be adjusted to the overall clinical context that 7 
includes the presence of hepatic co-morbidities/metabolic risk factors, other genetic factors as well as the 8 
presence/absence of baseline liver fibrosis as evaluated by non-invasive methods. The association with primary liver 9 
cancer should spur hepatological surveillance of both Pi*ZZ and Pi*SZ individuals. However, further studies are 10 
warranted to determine whether screening is needed for all Pi*SZ/Pi*ZZ individuals or only those with advanced 11 
liver fibrosis/cirrhosis. Longitudinal assessment is needed to define the rate of disease development and tumor 12 
occurrence in the individuals with different AATD genotypes.  13 
  14 
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FIGURE LEGENDS 1 
 2 
Figure 1: Overview of analyzed cohorts. 3 
A) Cohort 1: Population-based study analyzing UK Biobank participants aged 37 to 73 years at baseline. B) Cohort 4 
2: Prospectively recruited individuals available in a multinational, cross-sectional Alpha-1 Liver initiative. 5 
 6 
Figure 2: Liver related parameters in individuals heterozygous for the Pi*Z variant (Pi*MZ), homozygous for 7 
the Pi*S variant (Pi*SS), heterozygous for both Pi*S and Pi*Z (Pi*SZ), and homozygous for the Pi*Z variant 8 
(Pi*ZZ) compared to non-carriers (Cohort 1). 9 
422 506 non-carriers, 17 006 Pi*MZ subjects, 1014 Pi*SS individuals, 864 Pi*SZ subjects, and 138 Pi*ZZ 10 
individuals underwent laboratory analysis. P values were adjusted for age, sex, BMI, alcohol consumption, and 11 
presence of diabetes mellitus. Scatter plots of serum level of alanine aminotransferase (ALT; A), aspartate 12 
aminotransferase (AST; B), and alkaline phosphatase (ALP; C), all normalized to the sex-specific upper limit of 13 
normal (ULN).  14 
 15 
Figure 3: Risk of Pi*SS and Pi*SZ subjects to show elevated AST or ALT compared to heterozygous (Pi*MZ) 16 
and homozygous (Pi*ZZ) Pi*Z carriers as well as homozygous carriers of PNPLA3 p.I148M (rs738409), 17 
HSD17B13:T (rs72613567), and TM6SF2 p.E167K (rs5854926) (Cohort 1).  18 
Adjusted odds ratios (aOR) with their corresponding 95% confidence intervals (CI) are shown for aspartate 19 
aminotransferase (AST; A) and alanine aminotransferase (ALT; B). The risk to display levels higher than the 20 
corresponding sex-dependent upper limit of normal (ULN) was compared to the respective non-carriers. Odds ratios 21 
were adjusted for age, sex, BMI, alcohol consumption, and diabetes mellitus. 22 
 23 
Figure 4: Rate of Pi*SS and Pi*SZ subjects with decreased Tiffenau Index, elevated AST, or elevated ALT in 24 
different subpopulations (Cohort 1). 25 
Relative frequencies (%) are shown and visualized by a color coding (right panel). Decreased Tiffenau-index is 26 
defined as FEV1/VC <70%. Smokers are defined as “ever-smokers” and non-smokers are defined as “never-27 
smokers”. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index 28 




Figure 5: Odds ratios of ICD10 diagnoses in individuals heterozygous or homozygous for the Pi*Z variant 1 
(Pi*MZ/Pi*ZZ), homozygous for Pi*S variant (Pi*SS) and heterozygous for Pi*S and Pi*Z (Pi*SZ) (Cohort 2 
1). 3 
Adjusted odds ratios (aOR) with their corresponding 95% confidence intervals (CI) are shown for Pi*MZ, Pi*SS, 4 
Pi*SZ, and Pi*ZZ subjects compared to non-carriers. Odds ratios were adjusted for age, sex, BMI, alcohol 5 
consumption, and diabetes mellitus. If in one group no cases are available, the corresponding aOR was set as 1[1;1]. 6 
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Figure 6: Odds ratios of ICD10 diagnoses in individuals heterozygous (or homozygous for Pi*Z 8 
(Pi*MZ/Pi*ZZ), heterozygous for Pi*S and Pi*Z (Pi*SZ) or homozygous for displayed genetic liver fibrosis 9 
modifiers. 10 
Genetic liver fibrosis modifiers include PNPLA3 p.I148M (rs738409), HSD17B13:T (rs72613567),  and TM6SF2 11 
p.E167K (rs5854926)). Adjusted odds ratios (aOR) with their 95% confidence intervals (CI) compared to the 12 
corresponding non-carriers. Odds ratios were adjusted for age, sex, BMI, alcohol consumption, and diabetes mellitus.  13 
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